• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

ketamine treatments

May 19, 2022

Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022

TORONTO, ONTARIO May 19, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from May 24 – 26, 2022 in Miami, Florida. Braxia Scientific CEO Dr. Roger McIntyre will present an overview of the Company's business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression and expanding the clinical research infrastructure required to execute on the Company's growing pipeline of registered clinical trials alongside third-party sponsors. Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright...